Answers are grounded in this paper and cite their sources.
Background: Type 2 diabetes mellitus (T2DM) is a progressive metabolic disease in which the incretin effect is blunted. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 agonist tirzepatide restore incretin signalling and have reshaped treatment goals from glucose control alone toward weight reduction and organ protection. Objective: To summarise the pharmacology, glycaemic and non-glycaemic efficacy, safety, and clinical positioning of GLP-1 RAs and dual-incretin therapies, including agents approaching or reaching the market in 2026. Methods: A narrative review of landmark randomised trials, consensus guidelines, and recent pipeline reports, organised thematically. Findings: Long-acting GLP-1 RAs lower HbA1c by roughly 1 to 1.8 percentage points with clinically meaningful weight loss and a low intrinsic risk of hypoglycaemia. Several agents reduce major adverse cardiovascular events, and semaglutide reduces kidney outcomes in diabetic kidney disease. Tirzepatide produces larger reductions in HbA1c and weight than semaglutide in head-to-head testing. Gastrointestinal adverse effects are the main tolerability issue, while gallbladder disease, pancreatitis, retinopathy changes, and perioperative aspiration require attention. In 2026, the first oral small-molecule agent, orforglipron, was approved for weight management, and triple-agonist and amylin-combination therapies reported promising phase 3 data in T2DM. Conclusion: Incretin-based therapy is now a cornerstone of individualised T2DM management, particularly for people with obesity, cardiovascular, kidney, or liver disease. Access, cost, and long-term durability remain the key challenges.
No takes yet. Share an insight, caveat, or question.
Navale et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: